Medication use for comorbidities in people with Alzheimer's disease: an Australian population ‐based study

AbstractBackgroundPeople with Alzheimer's disease (AD) often have multimorbidity and take multiple medicines. Yet few studies have examined medicine utilization for comorbidities comparing people with and without AD.ObjectiveThe aim was to investigate the patterns of medication use for comorbidities in people with and without AD.MethodsAn Australian population ‐based study was conducted using the Pharmaceutical Benefits Scheme 10% sample of pharmacy claims data.People with ADwere defined as those dispensed medicines for dementia (cholinesterase inhibitors, memantine, or risperidone for behavioral and psychological symptoms of dementia) between January 1 , 2005 and December 31, 2015, who were aged 65 years or older and alive at the end of 2016. An age‐ and gender‐matched comparison cohort (5:1) of people without AD were identified.Medication use for comorbidities was identified using the validated comorbidity index, Rx‐Risk‐V. A χ2test was used to compare differences in the pattern of medicine use between the two groups.ResultsA total of 8280 people with AD and 41,400 comparisons without AD were included;63.4% were femaleand the median age was 82 years. The median number of comorbidities was greater in people with AD (median (interquartile range (IQR)): 5(3 ‐7)) than the comparison group (median (IQR): 4(3 – 6)), p
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: Original Research Article Source Type: research

Related Links:

Conditions:   Pain, Postoperative;   Tonsillar Bleeding;   Postoperative Nausea and Vomiting Interventions:   Drug: Dexamethasone;   Drug: Sodium chloride Sponsors:   Walid HABRE;   University Hospital, Geneva Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Malignant Neoplasm Interventions:   Drug: Fentanyl Sublingual Spray;   Drug: Morphine;   Other: Physical Performance Testing;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Insomnia Intervention:   Behavioral: Su-Man formula massage oil Sponsor:   China Medical University Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pain, Neuropathic Interventions:   Procedure: Stellate ganglion block;   Procedure: Sham Stellate ganglion block Sponsors:   Tanta University;   Mohamad Gamal Elmawy, M.D Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   D011471;   D064129;   D035683;   D009360;   D014408 Intervention:   Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor:   Azienda Ospedaliero-Universitaria Careggi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   End Stage Renal Disease Intervention:   Other: Presence of elbow pain in patients with end stage renal disease Sponsor:   Namik Kemal University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Metastatic Colorectal Cancer Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole Sponsors:   The Christie NHS Foundation Trust;   University of Manchester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Open Angle Glaucoma Interventions:   Biological: 2.5mg ANX007;   Biological: 5.0mg ANX007;   Other: Sham Procedure Sponsor:   Annexon, Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alzheimer's | Anxiety | Australia Health | Benign Prostatic Hyperplasia | Cancer | Cancer & Oncology | Chronic Pain | Dementia | Depression | Diabetes | Drugs & Pharmacology | Endocrinology | Epilepsy | Glaucoma | Gout | Hyperthyroidism | Namenda | Pain | Parkinson's Disease | Psychology | Risperdal Consta | Study